Breast cancer is the most common malignancy in women and the leading cause of death in women over 40 to 55 years old. Despite the advances and improvements in early detection and treatment, the incidence of this disease has increased and the mortality is unaltered. A clear understanding at the molecular and cellular levels of factors that regulate the growth and differentiation of breast cancer cells will provide insights into this complicated disease and may open new avenues for developing alternative treatments. Oncostatin M (OM), a cytokine produced by activated T-lymphocytes and macrophages has been shown to inhibit the growth of a number of breast cancer cell lines and primary breast tumor cells isolated from solid tumors or malignant effusions. The strong growth inhibitory and differentiative activities of OM on breast cancer cells and its unique source of production by activated mononuclear leukocytes suggest that this cytokine might be involved in a host defense to fight tumor progression in vivo. However, currently, little is known about the underlying principal of OM s antigrowth activity on breast cancer cells. The overall objectives of this proposal are to elucidate the molecular mechanisms how the OM antigrowth and differentiation signal is transduced from the membrane to the nucleus.
The specific aims of this proposal are threefold: (1) determine whether MAP kinase ERK plays a pivotal role in OM-induced growth inhibition and differentiation of breast cancer cells. Dominant negative mutants will be utilized to inhibit the activities of the endogenous proteins in the MAP kinase pathway and the STAT pathway, (2) identify ERK interacting proteins that are involved in breast cancer cell growth and differentiation by expression screening with activated ERK1 and [gamma-32P]ATP, and (3) identify the cis-acting elements and the trans-acting factors that mediate the suppressive effect of OM on c-myc transcription in breast cancer cells. These studies will provide important insights into the molecular mechanisms responsible for the actions of OM on the control of the growth and differentiation of breast cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA083648-01
Application #
6023969
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Mufson, R Allan
Project Start
2000-01-12
Project End
2004-12-31
Budget Start
2000-01-12
Budget End
2000-12-31
Support Year
1
Fiscal Year
2000
Total Cost
$157,944
Indirect Cost
Name
Palo Alto Institute for Research & Edu, Inc.
Department
Type
DUNS #
624218814
City
Palo Alto
State
CA
Country
United States
Zip Code
94304
Inaba, Satoru; Li, Cong; Shi, Y Eric et al. (2005) Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells. Breast Cancer Res Treat 94:25-35
Li, Cong; Lin, Meihong; Liu, Jingwen (2004) Identification of PRC1 as the p53 target gene uncovers a novel function of p53 in the regulation of cytokinesis. Oncogene 23:9336-47
Kong, Weijia; Wei, Jing; Abidi, Parveen et al. (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10:1344-51
Li, Cong; Zhang, Fang; Lin, Meihong et al. (2004) Induction of S100A9 gene expression by cytokine oncostatin M in breast cancer cells through the STAT3 signaling cascade. Breast Cancer Res Treat 87:123-34
Jiang, Yangfu; Liu, Yiliang Ellie; Lu, AiPing et al. (2003) Stimulation of estrogen receptor signaling by gamma synuclein. Cancer Res 63:3899-903
Gupta, Anu; Godwin, Andrew K; Vanderveer, Lisa et al. (2003) Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 63:664-73
Gupta, Anu; Inaba, Satoru; Wong, Oi Kwan et al. (2003) Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1. Oncogene 22:7593-9
Zhang, Fang; Lin, Meihong; Abidi, Parveen et al. (2003) Specific interaction of Egr1 and c/EBPbeta leads to the transcriptional activation of the human low density lipoprotein receptor gene. J Biol Chem 278:44246-54
Zhang, Fang; Li, Cong; Halfter, Hartmut et al. (2003) Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 22:894-905
Li, Cong; Shridhar, Kunju; Liu, Jingwen (2003) Molecular characterization of oncostatin M-induced growth arrest of MCF-7 cells expressing a temperature-sensitive mutant of p53. Breast Cancer Res Treat 80:23-37

Showing the most recent 10 out of 14 publications